secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001193125-26-043755
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar REZOLVE-AD maintenance data show durable EASI-75/90, vIGA-AD responses
-----------------------------------------------------------------------------

- 71% (monthly) and 83% (quarterly) maintained EASI-75 on 24 µg/kg; 85% and 63% maintained vIGA-AD 0/1.
- EASI-100 increased 2-5 fold: from 4% to 22% (monthly) and 9% to 18% (quarterly) in re-randomized patients.
- Discontinuation rate due to AEs was 3.5%; injection site reactions mostly mild; no new safety concerns.
- FDA alignment on Phase 3 design: 24 µg/kg Q2W induction, co-primary endpoints; start Q2 2026.
- New responses at Week 52: 51% new EASI-75 (monthly) and 39% (quarterly) support prolonged therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/0001193125-26-043755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/d103279d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-043755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer